Editorials
Clinical enzymology 1 'He that thoroughly understands the nature of Ferments and Fermentations, shall probably be mUch better able than he that ignores them, to give a fair account of divers Phenomena of several diseases.' This quotation from Robert Boyle (1627 1691) must be one of the earliest references to clinical enzymology which, however, found little application until the present century. First came Wohlgemuth's pioneer work on amylase and Garrod's inborn errors of metabolism, now shown to be due to enzyme defects. In the 1930s the diagnostic value of acid and .ilkaline phosphatases Was recognized, but it was the discovery of the diagnostic significance of 'rSpartate and alanine transaminases some twenty years later that marked the beginning of the modern phase of the subject.
This observation was important because it led to the realization that in a variety of diseases intracellular enzymes may be released into the cir-cUlating plasma. It inevitably produced its crop of fallacies, the most noteworthy being the concept that the appearance of intracellular enzymes in the plasma is indicative of tissue necrosis. In the literature of the late 1950s there are numerous references to such an interpretation of elevated plasma or serum enzyme activities. Clearly death of a cell leads to its disintegration and the discharge of its contents into the extracellular fluid, but the converse does not necessarily apply. It Soon became apparent that increased membrane permeabilities associated with inflammatory disorders, e.g. polymyositis, or impaired cellular nutrition or oxygenation due to ischaemia may also lead to enzyme leakage. Schmidt & Schmidt (1962) proposed that the presence of high activities of both mitochondrial and cytosolic enzymes in the plasma is suggestive of cell necrosis, while elevation in the cytosolic enzymes alone indicates increased membrane per-0141-0768/78/007 1-0241/$01.00 0 meability. A number of ratios of the activities of cytosolic and mitochondrial enzymes have found limited application in diagnosis, but lesions are rarely wholly necrotic or entirely inflammatory. Nevertheless a disproportionat e increase in the serum aspartate transaminase as compared with the serum alanine transaminase carries an ominous prognosis in viral hepatitis, since the former enzyme is found in both the cytosol and the mitochondria while alanine transaminase is almost entirely cytosolic.
lsoenzymes
The multiple forms of aspartate transaminase referred to above are examples of 'isoenzymes', The discovery of isoenzymes has added considerably to the tissue specificity of enzyme tests. The molecule of lactate dehydrogenase is a tetramer, made up of four subunits which may be of two different types, H (heart) and M (muscle). Hence five distinct isoenzymes occur: H 4 , HlM, H 2M 2 , HM 3 and M4• Thus the characteristic form of the heart enzyme, H4 , predominates in the sera of patients with myocardial infarction, while plasma M 4 is increased in liver diseases.
In normal serum, all five isoenzymes can be detected by electrophoresis (H 3M > H 4 > H 2M > HM 3 > M 4 ) · Numerous investigators have 2 re _ ported a shift towards the cationic forms (M and HM 3 ) in tumours and in the plasma of patients with malignant disease, and it has been suggested that such a change in the isoenzyme pattern of perimalignant tissues is indicative of a precancerous state (Latner et al. 1966 ). This alteration however, is not invariable, especially in certain brain and testicular tumours.
An example of~n unexpected isoenzyme pattern was .encountered In the serum of a patient with a carcinoma of the oesophagus with metastases in the liver (Fujimoto et al. 1968 ). Instead of a shift towards the cationic isoenzymes, marked increases were observed in the H 4 , H 3M and H M components, but additional bands with i nt~~edi ate mobilities were also detected. A sample of liver tumour removed at autopsy was found to exhibit a co~plete set of regularly-spaced isoenzymes, of which only the most anionic (H 4 ) showed its normal electrophoretic mobility. Further study suggested that the tumour had elaborated an abnormal form of M subunit, such that the abnormal M 4 isoenzyme migrated as fast as the normal HM 3 form. The extra bands detected in the serum thus appear to be hybrids of the normal H subunit with the abnormal M subunit. Such an occurrence might account for the detection of extra bands in the sera of patients with malignant disease previously reported by Beautyman (1962), Latner (1964) and others.
Creatine kinase is another enzyme the multiple forms of which are of diagnostic interest, but this enzyme has a dimeric molecule and only three forms (BB, MB and MM) can be detected electrophoretically.
Demonstration of increased circulating CK-MB is a highly specific test for myocardial damage (Konttinen & Somer 1972) but it makes heavy demands on laboratory resources and should normally be reserved for problem cases, e.g. after coronary by-pass surgery. Non-electrophoretic techniques are available, but selective activation of the enzyme with glutathione and dithiothreitol has been criticized as unsound. The alternative immuno-inhibition using a specific antiserum to the M subunit certainly determines half the activity of the MB isoenzyme, but in the rare event of the presence of significant amounts of the BB form in the plasma, the results would be liable to misinterpretation.
Release of enzymes from cells
Nearly 20 years ago Zierler (1958) demonstrated that intact rat muscles lost aldolase to the medium when subjected to a variety of insults, such as anoxia, deprivation of glucose and high potassium concentrations. These results suggest that increased membrane permeability is consequent upon reduction of the rate of ATP synthesis. i.e. a fall in the intracellular energy content. Evidence in support of this theory is provided by the marked increase in the rate of enzyme efflux from incubated human erythrocytes which occurs after the glucose concentration has fallen to negligible levels (Sweetin & Thomson 1973), and by the reduction of enzyme leakage which occurs when ATP is incorporated into the media in which rat lymphocytes or human leukocytes are incubated (Englhardt et af. 1969 , Wilkinson & Robinson 1974 . Other high-energy phosphates, e.g. phosphoenolpyruvate, also reduce enzyme leakage, and glucose also exerts a slight protective effect which is reversed in the presence of metabolic inhibitors, e.g, iodoacetate (Hallak & Wilkinson 1976a) .
Direct measurement of the intracellular ATP concentration in incubated cells has shown that there is little enzyme leakage until it has fallen to 20% or less of its original value, after which enzyme efflux is greatly increased (Wilkinson & Robinson 1974) .
There is thus strong evidence that the intracellular energy content plays an important part in protecting cells against loss of enzymes. It seems likely, therefore, that pathological processes interfering with cellular nutrition are likely to lead to its reduction and hence to the release of enzymes.
Before this theory can be accepted, however, some conflicting evidence must be considered. First, the cell membrane is generally considered to be impermeable to extracellular ATP. If this is true, the protective effect of its presence in the medium must be exerted on the external surface of the cell membrane where it might serve as a substrate for membrane-bound ATPase, thus conserving intracellular supplies. Secondly, AMP has been shown to reduce enzyme efflux from human lymphocytes in marked contrast to the increased release it causes in rat lymphocytes. Attempts to demonstrate conversion of AMP into ATP in the human cells by a system not present in the rat cells have proved inconclusive, and it seems that AMP may exert a direct effect on the permeability of the human cell membrane (Hallak & Wilkinson 1977) . Thirdly, lymphocytes from patients with chronic lymphocytic leukaemia lose enzymes at slower rates than normal lymphocytes during incubation, despite having significantly lower ATP contents. The additional coating on the leukaemic lymphocytes reported by Perera & Pegrum (1974) may play a part in reducing enzyme efflux. Incorporation of ATP into the medium has a similar protective effect on both leukaemic and normal cells (Hallak & Wilkinson 1976b) .
It seems, therefore, that the intracellular energy content is important in controlling membrane permeability, but it is evidently not the only factor concerned.
Catabolism of plasma enzymes
It is well recognized that enzymes disappear from the plasma at different rates after myocardial infarction or during recovery from an acute illness such as viral hepatitis, but until recently the mechanisms involved have been completely unknown. Excretion in the urine cannot occur in the absence of renal disease since, with the exception of certain enzymes of low molecular mass, e.g. amylase and uropepsinogen, enzyme molecules are too large to permit filtration by the glomerulus. Though liver alkaline phosphatase conjugated with a phospholipid is detectable in the bile (Price et al. 1972) , there is no evidence to suggest that biliary excretion is more than a minor pathway for enzyme clearance. Experimental studies have supported the view that excretory mechanisms are not involved (Strandjord et aI. 1959) , and Fleisher & Wakim (1963) suggested that the reticuloendothelial system might be concerned, but little evidence for this has since accrued. The suggestion that enzymes might undergo intravascular inactivation has therefore been proposed (Posen 1970 , Wilkinson 1970 .
At the risk of adding to my crop of fallacies. I shall describe some recent investigations aimed at testing this hypothesis. Radioactively-labelled enzymes were injected intravenously into rabbits and serial measurements of plasma radioactivity and catalytic activity were made to determine the fate of the enzyme protein after inactivation. Earlier work with 131 I-labelled enzymes (Schapira et al. 1962 . Massarat 1965 suggested that enzymes are removed intact from the circulation, and similar conclusions were reached by Boyd (1967) and Bar et al. (1972-3) , who injected lactate dehydrogenase-5 labelled by conjugation with a 14C_re_ agent. However. it now appears that 13lI-labelled enzymes suffer radioactive damage (Bar et al. 1972-3) and the conjugates seem to be rapidly hydrolysed in vivo (Qureshi & Wilkinson 1976b) .
After the administration of 12sI-labelled lactate dehydrogenase-5, Qureshi & Wilkinson (1976a) found the plasma radioactivity to disappear at a significantly slower rate (K, =0.057±S.D. 0.0II h -I) than the catalytic activity (K, = 0.19 ±S.D. 0.02 h -I). Since the disappearance rate of the latter was almost identical after injection of the unlabelled enzyme (K, =0.20 ±S.D. 0.02 h -1), it seems that the presence of the label does not affect the manner in which the enzyme is catabolized.
Plasma catalytic activity was also found to disappear more rapidly than plasma radioactivity after the administration of 12sI_labelled lactate dehydrogenase-I, though as expected from clinical observations, the removal of this isoenzyme was appreciably slower than that of isoenzyme-5 (Wilkinson & Qureshi 1976) .
It seems, therefore, that these isoenzymes are inactivated in the circulating blood or in a closely associated compartment. In both series of experiments tissue radioactivities were less than those in the plasma, suggesting that removal of inactivated enzyme protein is a passive rather than an active process. but appreciable concentrations were detected in the mucosae and contents of the small intestine. Despite this, little radioactivity appeared in the faeces, while after 72 hours about 70 0 0 of the dose was found in the urine, most of it as radioiodinated amino acids.
On the basis of these results it is proposed that enzymes undergo intravascular inactivation and that inactivated enzyme protein reaches the small intestine either directly via the mucosa or indirectly via the bile. Intestinal digestion follows and the resulting amino acids are reabsorbed, presumably to enter the amino acid pool. It remains to be seen whether the suggested mechanism applies to plasma enzymes generally and, more importantly, whether the human being gets rid of surplus enzymes in the same way. J H Wilkinson Department ofChemical Pathology Charing Cross Hospital Medical School London W68RF President Section of Pathology
